Background PD-1 blockade via pembrolizumab monotherapy has shown antitumour activity
and toxicity in patients with relapsed or refractory classical Hodgkin lymphoma. Here, we …

Purpose Classical Hodgkin lymphoma (HL) frequently exhibits genetic alterations leading to
overexpression of the programmed death-1 (PD-1) ligands, suggesting a possible …

The role of hematopoietic cell transplantation (HCT) in the therapy of Hodgkin lymphoma
(HL) in pediatric and adult patients is reviewed and critically evaluated in this systematic …

Relapsed or refractory Hodgkin lymphoma is a challenging problem for clinicians who treat
hematologic malignancies. The standard management of these patients should include the …

Despite the success of standard front-line chemotherapy for classical Hodgkin lymphoma
(cHL), a subset of these patients, particularly those with poor prognostic factors at diagnosis …

Despite the relatively high long-term disease-free survival (DFS) rate for patients with
Hodgkin lymphoma (HL) with modern combination chemotherapy or combined modality …

Background: Despite advances in therapy of Hodgkin's lymphoma (HL), a proportion of
patients will not respond or relapse. The authors had previously identified CD25, IL-2Rα, as …

Hodgkin's lymphoma (HL) is highly curable with first-line therapy. However, a minority of
patients present with refractory disease or experience relapse after completion of frontline …

Despite the well-defined role of autologous haematopoietic stem cell transplantation
(autoHCT) in the treatment of patients with relapsed or refractory Hodgkin lymphoma (HL) …

ABSTRACT Introduction Classical Hodgkin lymphoma (cHL) is a curable disease, with
durable remission achieved in about 80% of patients following first-line treatment. Three …